News – Page 1112 – Endpoints News

Pioneering Merck makes another breakthrough with PD-1 star Keytruda, grabbing first OK for a cancer biomarker

8 years ago

Hard charging Neurocrine hit with a sudden setback as Tourette study flops

8 years ago

AstraZeneca cheers a success for PhIII benralizumab study; TP raises $45M for cancer drug

8 years ago

Ludwig Hantson is cleaning house at Alexion, booting R&D chief Martin Mackay and other execs

8 years ago

Pfizer grabs a solid endorsement from FDA insiders for their knockoff of Amgen’s flagship drug Epogen

8 years ago

Adam Koppel and Jeff Schwartz are done raising capital. Now they have $720M to do some serious deals at Bain

8 years ago

Bioverativ beefs up its pipeline of rare blood disease drugs with $825M True North buyout

8 years ago

Trump administration doubles down on slashing the budget at NIH, FDA — with a user fee hike for biopharma

8 years ago

Eli Lilly-backed Symic raises $30M round as it preps for a pivotal trial

8 years ago

Regeneron, Sanofi win a delayed OK for rheumatoid arthritis IL-6 heavyweight sarilumab

8 years ago

FDA review raises some serious questions for Puma, but shares rocket up on positive notes

8 years ago

Ablynx grabs a €15M milestones payment from Merck KGaA; EyeGate surges on Valeant payout

8 years ago

On a deal spree, Takeda partners up with Nektar on a slate of cancer R&D combo studies

8 years ago

Shire writes off a shot at long-acting hemophilia drug after small study flops

8 years ago

Celgene scores another win for megablockbuster contender ozanimod, but it's haunted by key disability miss

8 years ago

La Jolla shares whacked as analysts spotlight disappointing PhIII fine print

8 years ago

Amgen’s star PhIII osteoporosis drug romo slammed by surprising cardio risk, a big plus for rival Radius drug

8 years ago

AbbVie preps an FDA pitch of promising PhIII data for blockbuster hopeful elagolix

8 years ago

Astellas, Pfizer scrap a PhIII breast cancer study using Xtandi; New $30M fund will back Israeli biotech startups

8 years ago

A father's plea: The FDA needs to make sure that Juno's lethal disaster isn't repeated

8 years ago

Top analyst says the tempest over drug prices will likely just die out without any major changes

8 years ago

The EMA rejects XBiotech’s cancer drug after an embarrassing PhIII — but they’re not giving up

8 years ago

Merck’s checkpoint star Keytruda grabs another FDA OK, steering past wreckage of a Roche disaster

8 years ago

Peer Review: Former FDA Commish Califf will split his time between Verily and Duke

8 years ago

First page Previous page 1109 1110 111111121113 1114 1115 Next page Last page